A breakthrough in Alzheimer’s disease has arrived with C2N Diagnostics’ PrecivityAD™ blood test into the clinic. The PrecivityAD™ test is a highly sensitive Alzheimer’s blood test using mass spectrometry and is performed in a CLIA-certified lab. The PrecivityAD™ test is easy to administer, does not involve any radiation, and is non-invasive. These features are expected to make the test more accessible than other diagnostic methods that physicians use to evaluate issues with memory and thinking.